Discovery & Development of S-4321, a Novel PD-1 FcgRIIb Dual Cell Bidirectional (DcB) Agonist Antibody

• Current approaches to checkpoint agonism in autoimmunity

• Concept of Dual Cell Bidirectional antibodies

• Discovery and development of S-4321, a novel PD-1 FcgRIIb dual cell bidirectional (DcB) agonist antibody

Speakers:

Jyothsna Visweswaraiah

Senior Director - Biotherapeutics & Drug Creation

Seismic Therapeutic